Personal information

No personal information available

Activities

Works (19)

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer

npj Precision Oncology
2024-11-17 | Journal article
Contributors: Takaaki Fujimura; Koh Furugaki; Hayato Mizuta; Satoshi Muraoka; Makoto Nishio; Jun Adachi; Ken Uchibori; Eisaku Miyauchi; Hidetoshi Hayashi; Ryohei Katayama et al.
Source: check_circle
Crossref

Serum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Cancers
2024-11-04 | Journal article
Contributors: Keiki Miyadera; Sho Kakuto; Mayu Sugai; Ryosuke Tsugitomi; Yoshiaki Amino; Ken Uchibori; Noriko Yanagitani; Hisatoshi Sugiura; Masahiro Seike; Makoto Nishio et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer

Biochemical and Biophysical Research Communications
2024-09 | Journal article
Contributors: Akari Shiraishi; Tomoko Oh-hara; Yuki Takahashi; Ken Uchibori; Makoto Nishio; Ryohei Katayama
Source: check_circle
Crossref

Distinction of ALK fusion gene‐ and EGFR mutation‐positive lung cancer with tumor markers

Thoracic Cancer
2024-04 | Journal article
Contributors: Takahiro Akita; Ryo Ariyasu; Sho Kakuto; Keiki Miyadera; Ayu Kiritani; Ryosuke Tsugitomi; Yoshiaki Amino; Ken Uchibori; Satoru Kitazono; Noriko Yanagitani et al.
Source: check_circle
Crossref

Efficacy of osimertinib in patients with EGFR‐mutation positive non‐small cell lung cancer with malignant pleural effusion

Thoracic Cancer
2024-02 | Journal article
Contributors: Ayu Kiritani; Yoshiaki Amino; Ken Uchibori; Takahiro Akita; Yuhei Harutani; Shinsuke Ogusu; Ryosuke Tsugitomi; Ryo Manabe; Ryo Ariyasu; Satoru Kitazono et al.
Source: check_circle
Crossref

A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer

npj Precision Oncology
2024-02-23 | Journal article
Contributors: Mai Suzuki; Ken Uchibori; Tomoko Oh-hara; Yumi Nomura; Ryusei Suzuki; Ai Takemoto; Mitsugu Araki; Shigeyuki Matsumoto; Yukari Sagae; Mutsuko Kukimoto-Niino et al.
Source: check_circle
Crossref

MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF

JCI Insight
2023-12-22 | Journal article
Contributors: Nobuyuki Kondo; Takahiro Utsumi; Yuki Shimizu; Ai Takemoto; Tomoko Oh-hara; Ken Uchibori; Sophia Subat-Motoshi; Hironori Ninomiya; Kengo Takeuchi; Makoto Nishio et al.
Source: check_circle
Crossref

Clinical characteristics of patients with KRAS mutation detected by liquid biopsy

Thoracic Cancer
2023-11 | Journal article
Contributors: Yoshiaki Amino; Siew‐Kee Low; Hironori Ninomiya; Ayu Kiritani; Keiki Miyadera; Sho Kakuto; Takahiro Akita; Ryosuke Tsugitomi; Ryo Ariyasu; Ken Uchibori et al.
Source: check_circle
Crossref

Targeting ErbB and tankyrase1/2 prevent the emergence of drug tolerant persister cells in ALK fusion positive lung cancer

2023-09-19 | Preprint
Contributors: Shigeki Yoshiura; Takaaki Fujimura; Koh Furugaki; Hayato Mizuta; Makoto Nishio; Ken Uchibori; Eisaku Miyauchi; Hidetoshi Hayashi; Ryohei Katayama
Source: check_circle
Crossref

A phase II feasibility study of carboplatin and nab‐paclitaxel for advanced non‐small cell lung cancer patients with interstitial lung disease (YLOG0114)

Thoracic Cancer
2022-05 | Journal article
Contributors: Hiroyuki Sakashita; Ken Uchibori; Yasuto Jin; Toshiharu Tsutsui; Takayuki Honda; Rie Sakakibara; Takahiro Mitsumura; Yoshihisa Nukui; Tsuyoshi Shirai; Masahiro Masuo et al.
Source: check_circle
Crossref

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer

npj Precision Oncology
2022-03-17 | Journal article
Contributors: Yuki Shimizu; Koutaroh Okada; Jun Adachi; Yuichi Abe; Ryohei Narumi; Ken Uchibori; Noriko Yanagitani; Sumie Koike; Satoshi Takagi; Makoto Nishio et al.
Source: check_circle
Crossref

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity

npj Precision Oncology
2021-12 | Journal article
Part of ISSN: 2397-768X
Source: Self-asserted source
Ken Uchibori

Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR

Cancer Science
2021-06 | Journal article
Part of ISSN: 1347-9032
Part of ISSN: 1349-7006
Source: Self-asserted source
Ken Uchibori

Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2

Thoracic Cancer
2021-03 | Journal article
Contributors: Ken Uchibori; Natsuki Takano; Ryo Manabe; Ryosuke Tsugitomi; Shinsuke Ogusu; Takehiro Tozuka; Hiroaki Sakamoto; Hiroshi Yoshida; Yoshiaki Amino; Ryo Ariyasu et al.
Source: check_circle
Crossref

Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice

Thoracic Cancer
2021-02 | Journal article
Contributors: Ryo Ariyasu; Ken Uchibori; Hironori Ninomiya; Shinsuke Ogusu; Ryosuke Tsugitomi; Ryo Manabe; Hiroaki Sakamaoto; Takehiro Tozuka; Hiroshi Yoshida; Yoshiaki Amino et al.
Source: check_circle
Crossref

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms

Cancer Science
2020-03 | Journal article
Part of ISSN: 1347-9032
Part of ISSN: 1349-7006
Source: Self-asserted source
Ken Uchibori

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer

Thoracic Cancer
2020-03 | Journal article
Part of ISSN: 1759-7706
Part of ISSN: 1759-7714
Source: Self-asserted source
Ken Uchibori

Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody

Lung Cancer
2019-07 | Journal article
Contributors: Masafumi Saiki; Takahiro Yoshizawa; Yosuke Dotsu; Ryo Ariyasu; Junji Koyama; Tomoaki Sonoda; Ken Uchibori; Shingo Nishikawa; Satoru Kitazono; Noriko Yanagitani et al.
Source: check_circle
Crossref

Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations

Lung Cancer
2018-10 | Journal article
Contributors: Ken Uchibori; Miyako Satouchi; Naoko Sueoka-Aragane; Yoshiko Urata; Akemi Sato; Fumio Imamura; Takako Inoue; Motoko Tachihara; Kazuyuki Kobayashi; Nobuyuki Katakami et al.
Source: check_circle
Crossref

Peer review (1 review for 1 publication/grant)

Review activity for npj precision oncology. (1)